These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 32950598)

  • 1. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
    Boila LD; Sengupta A
    Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
    Tsai CT; So CW
    Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
    Pastore F; Levine RL
    Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting histone methylation and demethylation for non-alcoholic fatty liver disease.
    Du Y; He Z; Jin S; Jin G; Wang K; Yang F; Zhang J
    Bioorg Chem; 2024 Oct; 151():107698. PubMed ID: 39126869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options.
    Hayatigolkhatmi K; Valzelli R; El Menna O; Minucci S
    Int Rev Cell Mol Biol; 2024; 387():27-75. PubMed ID: 39179348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
    Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
    Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
    Boila LD; Chatterjee SS; Banerjee D; Sengupta A
    Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
    Kim TK; Gore SD; Zeidan AM
    Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
    Castelli G; Pelosi E; Testa U
    Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.
    van Dijk AD; Hoff FW; Qiu YH; Chandra J; Jabbour E; de Bont ESJM; Horton TM; Kornblau SM
    Clin Epigenetics; 2021 Jan; 13(1):21. PubMed ID: 33509276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.